Loading...
•
Mar 31
Akoya Q1 2025 Earnings Report
Akoya Biosciences reports first quarter 2025 financial results with a decrease in revenue and net loss, alongside an increase in gross margin.
Key Takeaways
Akoya Biosciences reported a revenue of $16.6 million for the first quarter of 2025, a decrease of 9.8% compared to the prior year. The company's net loss improved to -$15.652 million from -$23.484 million in the prior year period, and gross margin increased significantly to 59.3%.
Revenue for Q1 2025 was $16.6 million, down 9.8% year-over-year.
Gross margin improved to 59.3% in Q1 2025, up from 45.7% in the prior year period.
Net loss for Q1 2025 was -$15.652 million, an improvement from -$23.484 million in the prior year.
Operating expenses decreased by 22.3% to $23.3 million in Q1 2025.
Akoya
Akoya
Akoya Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.comService and other Revenue
CapyFin.com Forward Guidance
Akoya will not be hosting an earnings conference call or providing forward-looking guidance at this time due to the pending acquisition by Quanterix Corporation.
Positive Outlook
- Continued focus on operational discipline and innovation.
- Successful increase in installed base despite macroeconomic uncertainty.
- Technology gaining momentum globally, with growing adoption in large-scale population studies.
- Expanding publication footprint across key research areas in high-impact journals.
- Confidence in value-creating opportunities from the integration with Quanterix.
Challenges Ahead
- Broader macroeconomic uncertainty.
- NIH funding uncertainty.
- Pending acquisition by Quanterix Corporation means no earnings call.
- No forward-looking guidance provided at this time.
- Potential risks and uncertainties related to the proposed merger.
Revenue & Expenses
Visualization of income flow from segment revenue to net income